C
Can Fite Biopharma Ltd
TASE:CANF
Can Fite Biopharma Ltd
TASE:CANF
Price:
538.4
ILS
-0.3%
Market Closed
Market Cap:
₪22.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
IL |
|
Honest Company Inc
NASDAQ:HNST
|
US |
|
Wayfair Inc
NYSE:W
|
US |
|
C
|
Coincheck Group NV
NASDAQ:CNCK
|
NL |
|
G
|
Guangdong Huiyun Titanium Industry Co Ltd
SZSE:300891
|
CN |
|
V
|
Visco Vision Inc
TWSE:6782
|
TW |
|
Horseshoe Metals Ltd
ASX:HOR
|
AU |
|
ABC India Ltd
BSE:520123
|
IN |
|
Austco Healthcare Ltd
ASX:AHC
|
AU |
|
Linius Technologies Ltd
ASX:LNU
|
AU |
|
Transense Technologies PLC
LSE:TRT
|
UK |
|
S
|
Sangshin Electronics Co Ltd
KOSDAQ:263810
|
KR |
|
Alvopetro Energy Ltd
XTSX:ALV
|
CA |
|
Brooks Macdonald Group PLC
LSE:BRK
|
UK |
Balance Sheet
Balance Sheet Decomposition
Can Fite Biopharma Ltd
Can Fite Biopharma Ltd
Balance Sheet Decomposition is not available for
Can Fite Biopharma Ltd
Can Fite Biopharma Ltd
Balance Sheet
Can Fite Biopharma Ltd
Can Fite Biopharma Ltd
Currency: USD
| Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||
| Cash & Cash Equivalents |
2
|
1
|
8
|
2
|
12
|
5
|
5
|
0
|
0
|
1
|
6
|
10
|
20
|
9
|
4
|
4
|
3
|
0
|
0
|
0
|
4
|
5
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
2
|
1
|
8
|
2
|
12
|
5
|
5
|
0
|
0
|
0
|
6
|
10
|
20
|
9
|
4
|
4
|
3
|
0
|
0
|
0
|
4
|
5
|
|
| Short-Term Investments |
0
|
0
|
0
|
7
|
0
|
0
|
0
|
5
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
2
|
3
|
4
|
4
|
1
|
15
|
6
|
6
|
4
|
|
| Total Current Assets |
2
|
1
|
8
|
10
|
12
|
6
|
5
|
5
|
5
|
2
|
7
|
11
|
21
|
11
|
7
|
8
|
7
|
9
|
20
|
9
|
10
|
9
|
|
| PP&E Net |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
3
N/A
|
1
-55%
|
8
+555%
|
10
+23%
|
13
+28%
|
6
-54%
|
5
-8%
|
5
-1%
|
5
-7%
|
2
-67%
|
7
+307%
|
11
+66%
|
21
+91%
|
11
-46%
|
8
-33%
|
8
+4%
|
8
+3%
|
10
+17%
|
20
+113%
|
9
-54%
|
10
+8%
|
9
-9%
|
|
| Liabilities | |||||||||||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
1
|
2
|
1
|
1
|
1
|
0
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Short-Term Debt |
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
1
|
0
|
|
| Total Current Liabilities |
1
|
3
|
0
|
1
|
2
|
2
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
2
|
3
|
3
|
1
|
3
|
3
|
2
|
2
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
2
|
6
|
4
|
1
|
2
|
2
|
2
|
3
|
2
|
2
|
2
|
|
| Total Liabilities |
1
N/A
|
3
+360%
|
0
-91%
|
1
+200%
|
2
+183%
|
2
-18%
|
2
-6%
|
2
-11%
|
2
+41%
|
3
+32%
|
3
-1%
|
4
+41%
|
9
+117%
|
7
-19%
|
3
-63%
|
5
+90%
|
6
+16%
|
3
-40%
|
6
+70%
|
5
-18%
|
4
-22%
|
4
-2%
|
|
| Equity | |||||||||||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
8
|
33
|
61
|
0
|
0
|
0
|
|
| Retained Earnings |
14
|
18
|
19
|
26
|
39
|
45
|
49
|
56
|
57
|
63
|
74
|
80
|
93
|
96
|
88
|
95
|
110
|
125
|
141
|
151
|
158
|
166
|
|
| Additional Paid In Capital |
16
|
16
|
27
|
35
|
49
|
48
|
52
|
60
|
60
|
63
|
77
|
84
|
102
|
97
|
81
|
82
|
103
|
97
|
93
|
154
|
164
|
171
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
10
|
14
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Equity |
2
N/A
|
2
N/A
|
8
N/A
|
9
+17%
|
10
+14%
|
4
-62%
|
4
-9%
|
4
+4%
|
3
-27%
|
1
N/A
|
4
N/A
|
7
+84%
|
12
+76%
|
4
-65%
|
5
+15%
|
3
-40%
|
2
-19%
|
6
+149%
|
14
+137%
|
4
-69%
|
6
+40%
|
5
-13%
|
|
| Total Liabilities & Equity |
3
N/A
|
1
-55%
|
8
+555%
|
10
+23%
|
13
+28%
|
6
-54%
|
5
-8%
|
5
-1%
|
5
-7%
|
2
-67%
|
7
+307%
|
11
+66%
|
21
+91%
|
11
-46%
|
8
-33%
|
8
+4%
|
8
+3%
|
10
+17%
|
20
+113%
|
9
-54%
|
10
+8%
|
9
-9%
|
|
| Shares Outstanding | |||||||||||||||||||||||
| Common Shares Outstanding |
5
|
5
|
5
|
6
|
8
|
8
|
9
|
9
|
10
|
10
|
18
|
21
|
28
|
28
|
33
|
40
|
121
|
464
|
816
|
0
|
0
|
1
|
|
Switch to:
Switch to:
See Also
Discover More
